New Delhi, March 10 -- Indian pharma companies like CDMOs (Contract Development and Manufacturing Organizations) will not see major disruptions from the proposed US tariffs of 10-25 per cent, according to a report by B&K Securities.

The report highlighted that Indian pharma services companies will continue to benefit from favourable global factors despite concerns over new trade restrictions.

It said "The companies see only marginal impact and no major disruption to US business from the planned US tariffs (10-25 per cent)".

The US remains a key market for Indian CDMO players, with exports worth approximately USD 9-10 billion annually. While the tariff proposal has raised concerns, Indian firms expect only a marginal impact on their bus...